



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Gerald Horn

Appl. No.: 09/854,414

Conf. No.: 7675

Filed: May 10, 2001

Title: OPHTHALMIC FORMULATIONS COMPRISING IMIDAZOLINE

Art Unit: 1614

Examiner: Z. Fay

Docket No.: 114309-1007

RECEIVED
APR 14 2003
TECH CENTER 1600/2900

12/C
JRP
5/8/03

Commissioner for Patents
Washington, DC 20231

RESPONSE TO OFFICE ACTION

Sir:

In response to the Office Action dated October 2, 2002, please amend the above-identified patent application as follows:

In the Claims:

Please amend claims 1, 10, 23, 34, 37, 41 and 43 as follows:

1. (Amended) An ophthalmic formulation, comprising:

a1 a first active compound including an alpha 1 antagonist capable of reducing dilation of a human eye exposed to a low light environment as compared to dilation which naturally occurs absent the compound and generating a redness response of about +1 or less on a scale of 0 to +4.

10. (Amended) A method of modulating pupil dilation, comprising:

a2 administering to an eye of a patient a formulation comprising a first compound including an alpha 1 antagonist capable of disrupting an endogenous compound which stimulates a dilator muscle of the eye; and

allowing the formulation to remain in contact with the eye for a period of time and under lighting conditions where the dilator muscles would be stimulated in the absence of the formulation;